Skip to main content
Back
Watch Compare

BioNexus Gene Lab Corp

Data quality: 100%
BGLC
Nasdaq Services Health Services
$2.25
▼ $0.06 (-2.64%)
Mkt Cap: 5.32 M
Price
$2.25
Mkt Cap
5.32 M
Day Range
$2.15 — $2.26
52-Week Range
$1.92 — $15.60
Volume
3,150
Open $2.16
50D / 200D Avg
$2.42
7.04% below
50D / 200D Avg
$4.28
47.43% below

Quick Summary

Key Takeaways

Revenue declined -4.41% annually over 5 years
Negative free cash flow of -2.91 M
Capital efficient — spends only 0.42% of revenue on capex

Growth

Revenue Growth (5Y)
-4.41%
Below sector avg (19.14%)
Revenue (1Y)-2.66%
Earnings (1Y)N/A
FCF Growth (3Y)N/A

Quality

Return on Equity
-32.04%
Below sector avg (-1.53%)
ROIC-25.40%
Net Margin-24.27%
Op. Margin-24.81%

Safety

Debt / Equity
N/A
Current Ratio8.30
Interest CoverageN/A

Valuation

PE (TTM)
-2.31
Below sector avg (-0.01)
P/B Ratio0.78
EV/EBITDAN/A
Dividend YieldN/A

Price History

Financial Trends

Peer Comparison

vs Services sector median (20 peers)
Metric Stock Sector Median
P/E -2.3 0.0
P/B 0.8 3.1
ROE % -32.0 -1.5
Net Margin % -24.3 -0.3
Rev Growth 5Y % -4.4 19.1
D/E — 1.0

All Fundamental Metrics
Growth
Revenue Growth (1Y) -2.66% Revenue Growth (3Y) -6.71%
Earnings Growth (1Y) N/A Earnings Growth (3Y) N/A
Revenue Growth (5Y) -4.41% Earnings Growth (5Y) N/A
Profitability
Revenue (TTM) 9.47 M Net Income (TTM) -2.30 M
ROE -32.04% ROA -26.95%
Gross Margin 14.77% Operating Margin -24.81%
Net Margin -24.27% Free Cash Flow (TTM) -2.91 M
ROIC -25.40% FCF Growth (3Y) N/A
Safety
Debt / Equity N/A Current Ratio 8.30
Interest Coverage N/A Asset Turnover 1.11
Working Capital 4.95 M Tangible Book Value 6.82 M
Dividends
Dividend Yield N/A Payout Ratio N/A
Dividend Growth (3Y) N/A Dividend Growth (5Y) N/A
Consecutive Div Years N/A
Valuation
P/E Ratio -2.31 Forward P/E N/A
P/B Ratio 0.78 P/S Ratio 0.56
PEG Ratio N/A Forward PEG N/A
EV/EBITDA N/A Fwd EV/EBITDA N/A
Forward P/S N/A Fwd Earnings Yield N/A
FCF Yield -54.72%
Market Cap 5.32 M Enterprise Value 5.32 M
Per Share
EPS (Diluted TTM) -1.18 Revenue / Share 4.00
FCF / Share -1.23 OCF / Share -1.21
EPS CAGR (1Y) N/A EPS CAGR (5Y) N/A
EPS CAGR (10Y) N/A
Efficiency
CapEx / Revenue 0.42% FCF Conversion 126.66%
SBC-Adj. FCF -3.05 M Growth Momentum 1.75

Income Statement

Annual, most recent first
Metric FY2024 FY2023 FY2022 FY2020 FY2021
Revenue 9.51 M 9.77 M 10.93 M 11.39 M 13.36 M
Net Income -1.60 M -2.63 M -355,966.0 1.09 M 751,571.0
EPS (Diluted) -0.09 — — — —
Gross Profit 1.29 M 1.33 M 1.26 M 1.72 M 2.19 M
Operating Income -1.57 M -2.59 M -291,177.0 1.27 M 1.06 M
EBITDA — — — — —
R&D Expenses 47,511.0 — — — —
SG&A Expenses — — — — —
D&A — — — — —
Interest Expense — 13,929.0 — — —
Income Tax -3,494.0 -21,526.0 -52,310.0 — —

Balance Sheet

Annual, most recent first
Metric FY2024 FY2023 FY2022 FY2020 FY2021
Total Assets 10.43 M 11.40 M 8.74 M 10.12 M 9.57 M
Total Liabilities 2.11 M 1.74 M 2.08 M 3.45 M 2.39 M
Shareholders' Equity 8.32 M 9.66 M 6.67 M 6.66 M 7.18 M
Total Debt — — — — —
Cash & Equivalents — — — 2.79 M 2.12 M
Current Assets 7.43 M 8.05 M 6.02 M 7.99 M 7.15 M
Current Liabilities 1.95 M 1.63 M 2.00 M 3.37 M 2.33 M